OTLC · Oncotelic Therapeutics, Inc.
$0.03
0.00 (-0.32%)
At close · Aug 28
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of one year from the date of this filing.”View the 10-Q filed Aug 13, 2026
Market Cap
$13.73M
Shares
457.51M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Fatih Uckun, MD, Ph. D | Chief Medical Officer ("CMO") | Resigned | 2023-03-02 |
| Seymour Fein, M.D. | Consulting Chief Regulatory Officer | Appointed | 2022-05-06 |
| Fatih Uckun, M.D., Ph.D. | Consulting Chief Medical Officer | Appointed | 2022-05-06 |
| David Diamond | a member of the Board | Resigned | 2021-07-20 |
| Chulho Park, Ph. D. | Chief Technology Officer | Resigned | 2021-07-02 |
| Anthony E. Maida, III | Board of Directors | Appointed | 2020-05-14 |
| Steven W. King | Board of Directors | Appointed | 2020-05-14 |
| David Diamond | the Board of the Company | Appointed | 2020-01-22 |
| William D. Schwieterman | member of the Board of Directors | Resigned | 2020-01-22 |
| Seymour Fein | Chief Medical Officer | Appointed | 2020-01-09 |
| Fatih Uckun | Chief Medical Officer | Resigned | 2020-01-09 |
| Dr. Fatih Uckun | Chief Medical Officer | Resigned | 2020-01-06 |